Randomized, double-blind, placebo-controlled, multi-center, sequential cohort study to evaluate the effect of SLV320 in addition to chronic furosemide treatment on renal function in subjects with congestive heart failure and impaired renal function.

Trial Profile

Randomized, double-blind, placebo-controlled, multi-center, sequential cohort study to evaluate the effect of SLV320 in addition to chronic furosemide treatment on renal function in subjects with congestive heart failure and impaired renal function.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs SLV 320 (Primary)
  • Indications Heart failure
  • Focus Biomarker; Therapeutic Use
  • Sponsors Abbott Healthcare Products
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Mar 2008 Status changed from suspended to discontinued.
    • 15 Feb 2008 Status changed from recruiting to suspended, as reported in ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top